Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Возможности улучшения качества жизни при атопическом дерматите
Возможности улучшения качества жизни при атопическом дерматите
Дворянкова Е.В., Мильдзихова Д.Р., Корсунская И.М. Возможности улучшения качества жизни при атопическом дерматите. Consilium Medicum. Дерматология (Прил.). 2016; 4: 5–8.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В работе проводится подробный разбор современных увлажняющих средств и их возможностей в терапии атопического дерматита (АД), а также их влияния на течение заболевания. Рационально подобранное средство может купировать основные проявления АД (гиперемия, зуд и т.д.), что положительно сказывается на качестве жизни не только пациента, но и окружающих.
________________________________________________
Полный текст
Список литературы
1. Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 2013; 70 (1): 3–11.
2. Vijayanand P, Seumois G, Simpson LJ et al. Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity 2012; 36 (2): 175–87.
3. Решетило О.В., Стоева Т.В., Весилык Н.Л. Влияние атопического дерматита на качество жизни детей и родителей. Междунар. научно-исследовательский журн. 2015; 9 (40): 65–7. / Reshetilo O.V., Stoeva T.V., Vesilyk N.L. Vliianie atopicheskogo dermatita na kachestvo zhizni detei i roditelei. Mezhdunar. nauchno-issledovatel'skii zhurn. 2015; 9 (40): 65–7. [in Russian]
4. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60 (8): 984–92.
5. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118 (1): 152–69.
6. Guidelines for treatment of atopic eczema (atopic dermatitis); part I.
7. Ring J, Alomar A, Bieber T et al. European Dermatology Forum (EDF), European Academy of Dermatology and Venereology (EADV), European Federation of Allergy (EFA), European Task Force on Atopic Dermatitis (ETFAD), European Society of Pediatric Dermatology (ESPD). Global Allergy and Asthma European Network (GA2LEN). J Eur Acad Dermatol Venereol 2012; 26 (8): 1045–60.
8. Rubel D, Thirumoorthy T, Soebaryo RW et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. Asia-Pacific Consensus Group for Atopic Dermatitis. J Dermatol 2013; 40 (Issue 3): 160–71. DOI: 10.1111/1346-8138.12065
9. Moncrieff G, Cork M, Lawton S et al. Use of emollients in dry-skin conditions: consensus statement. Clin Exp Dermatol 2013; 38: 231–8.
10. Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol 2012; 30: 286–96.
11. Giam YC, Hebert AA, Dizon MV et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy 2016; 6 (2): 120–8.
12. Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol 2013; 31: 91–8.
13. Vickery BP. Skin barrier function in atopic dermatitis. Curr Opin Ped 2007; 19: 89–93.
14. Vu AT, Baba T, Chen X et al. Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 2010; 126: 985–93.
15. Kozman A, Yao Y, Bina P et al. Encoding a superantigen by Staphylococcus aureus does not affect clinical characteristics of infected atopic dermatitis lesions. Br J Dermatol 2010; 163: 1308–11.
16. Hachem JP, Crumrine D, Fluhr J et al. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity cohesion. J Invest Dermatol 2003; 121: 345–53.
17. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol 2005; 99: 703–15.
18. Погосян М.А. Хлоргексидин – антисептик, не приводящий к бактериорезистенстности. Бюллетень мед. Интернет-конференций. 2015; 5 (10): 1234–5. / Pogosyan M.A. Khlorgeksidin – antiseptik, ne privodiashchii k bakteriorezistenstnosti. Biulleten' med. Internet-konferentsii. 2015; 5 (10): 1234–5. [in Russian]
19. Putet G, Guy B et al. Effect of Bepanten Ointment on the prevention and treatment of diaper rash on premature and full-term babies. Realites Pediatriques 2001; 63: 33–8.
20. Зайцева С.В., Застрожина А.К., Муртазаева О.А. Особенности кожного барьера у ребенка раннего возраста. Мед. совет. 2015; 6: 18–23. / Zaytseva S.V., Zastrozhina A.K., Murtazaeva O.A. Osobennosti kozhnogo bar'era u rebenka rannego vozrasta. Med. sovet. 2015; 6: 18–23. [in Russian]
21. Иванова Н.А., Костракина Л.Н. Опыт применения Бепантена и Бепантена плюс в лечении атопического дерматита у детей. Сonsilium Medicum. Педиатрия (Прил.). 2005; 1: 39–41. / Ivanova N.A., Kostrakina L.N. Opyt primeneniia Bepantena i Bepantena plius v lechenii atopicheskogo dermatita u detei. Sonsilium Medicum. Pediatrics (Suppl.). 2005; 1: 39–41. [in Russian]
22. Lynde C, Barber K, Claveau J et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg 2005; 8 (Suppl. 5): 1–9: 12.
2. Vijayanand P, Seumois G, Simpson LJ et al. Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity 2012; 36 (2): 175–87.
3. Reshetilo O.V., Stoeva T.V., Vesilyk N.L. Vliianie atopicheskogo dermatita na kachestvo zhizni detei i roditelei. Mezhdunar. nauchno-issledovatel'skii zhurn. 2015; 9 (40): 65–7. [in Russian]
4. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60 (8): 984–92.
5. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118 (1): 152–69.
6. Guidelines for treatment of atopic eczema (atopic dermatitis); part I.
7. Ring J, Alomar A, Bieber T et al. European Dermatology Forum (EDF), European Academy of Dermatology and Venereology (EADV), European Federation of Allergy (EFA), European Task Force on Atopic Dermatitis (ETFAD), European Society of Pediatric Dermatology (ESPD). Global Allergy and Asthma European Network (GA2LEN). J Eur Acad Dermatol Venereol 2012; 26 (8): 1045–60.
8. Rubel D, Thirumoorthy T, Soebaryo RW et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. Asia-Pacific Consensus Group for Atopic Dermatitis. J Dermatol 2013; 40 (Issue 3): 160–71. DOI: 10.1111/1346-8138.12065
9. Moncrieff G, Cork M, Lawton S et al. Use of emollients in dry-skin conditions: consensus statement. Clin Exp Dermatol 2013; 38: 231–8.
10. Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol 2012; 30: 286–96.
11. Giam YC, Hebert AA, Dizon MV et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy 2016; 6 (2): 120–8.
12. Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol 2013; 31: 91–8.
13. Vickery BP. Skin barrier function in atopic dermatitis. Curr Opin Ped 2007; 19: 89–93.
14. Vu AT, Baba T, Chen X et al. Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 2010; 126: 985–93.
15. Kozman A, Yao Y, Bina P et al. Encoding a superantigen by Staphylococcus aureus does not affect clinical characteristics of infected atopic dermatitis lesions. Br J Dermatol 2010; 163: 1308–11.
16. Hachem JP, Crumrine D, Fluhr J et al. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity cohesion. J Invest Dermatol 2003; 121: 345–53.
17. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol 2005; 99: 703–15.
18. Pogosyan M.A. Khlorgeksidin – antiseptik, ne privodiashchii k bakteriorezistenstnosti. Biulleten' med. Internet-konferentsii. 2015; 5 (10): 1234–5. [in Russian]
19. Putet G, Guy B et al. Effect of Bepanten Ointment on the prevention and treatment of diaper rash on premature and full-term babies. Realites Pediatriques 2001; 63: 33–8.
20. Zaytseva S.V., Zastrozhina A.K., Murtazaeva O.A. Osobennosti kozhnogo bar'era u rebenka rannego vozrasta. Med. sovet. 2015; 6: 18–23. [in Russian]
21. Ivanova N.A., Kostrakina L.N. Opyt primeneniia Bepantena i Bepantena plius v lechenii atopicheskogo dermatita u detei. Sonsilium Medicum. Pediatrics (Suppl.). 2005; 1: 39–41. [in Russian]
22. Lynde C, Barber K, Claveau J et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg 2005; 8 (Suppl. 5): 1–9: 12.
2. Vijayanand P, Seumois G, Simpson LJ et al. Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity 2012; 36 (2): 175–87.
3. Решетило О.В., Стоева Т.В., Весилык Н.Л. Влияние атопического дерматита на качество жизни детей и родителей. Междунар. научно-исследовательский журн. 2015; 9 (40): 65–7. / Reshetilo O.V., Stoeva T.V., Vesilyk N.L. Vliianie atopicheskogo dermatita na kachestvo zhizni detei i roditelei. Mezhdunar. nauchno-issledovatel'skii zhurn. 2015; 9 (40): 65–7. [in Russian]
4. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60 (8): 984–92.
5. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118 (1): 152–69.
6. Guidelines for treatment of atopic eczema (atopic dermatitis); part I.
7. Ring J, Alomar A, Bieber T et al. European Dermatology Forum (EDF), European Academy of Dermatology and Venereology (EADV), European Federation of Allergy (EFA), European Task Force on Atopic Dermatitis (ETFAD), European Society of Pediatric Dermatology (ESPD). Global Allergy and Asthma European Network (GA2LEN). J Eur Acad Dermatol Venereol 2012; 26 (8): 1045–60.
8. Rubel D, Thirumoorthy T, Soebaryo RW et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. Asia-Pacific Consensus Group for Atopic Dermatitis. J Dermatol 2013; 40 (Issue 3): 160–71. DOI: 10.1111/1346-8138.12065
9. Moncrieff G, Cork M, Lawton S et al. Use of emollients in dry-skin conditions: consensus statement. Clin Exp Dermatol 2013; 38: 231–8.
10. Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol 2012; 30: 286–96.
11. Giam YC, Hebert AA, Dizon MV et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy 2016; 6 (2): 120–8.
12. Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol 2013; 31: 91–8.
13. Vickery BP. Skin barrier function in atopic dermatitis. Curr Opin Ped 2007; 19: 89–93.
14. Vu AT, Baba T, Chen X et al. Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 2010; 126: 985–93.
15. Kozman A, Yao Y, Bina P et al. Encoding a superantigen by Staphylococcus aureus does not affect clinical characteristics of infected atopic dermatitis lesions. Br J Dermatol 2010; 163: 1308–11.
16. Hachem JP, Crumrine D, Fluhr J et al. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity cohesion. J Invest Dermatol 2003; 121: 345–53.
17. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol 2005; 99: 703–15.
18. Погосян М.А. Хлоргексидин – антисептик, не приводящий к бактериорезистенстности. Бюллетень мед. Интернет-конференций. 2015; 5 (10): 1234–5. / Pogosyan M.A. Khlorgeksidin – antiseptik, ne privodiashchii k bakteriorezistenstnosti. Biulleten' med. Internet-konferentsii. 2015; 5 (10): 1234–5. [in Russian]
19. Putet G, Guy B et al. Effect of Bepanten Ointment on the prevention and treatment of diaper rash on premature and full-term babies. Realites Pediatriques 2001; 63: 33–8.
20. Зайцева С.В., Застрожина А.К., Муртазаева О.А. Особенности кожного барьера у ребенка раннего возраста. Мед. совет. 2015; 6: 18–23. / Zaytseva S.V., Zastrozhina A.K., Murtazaeva O.A. Osobennosti kozhnogo bar'era u rebenka rannego vozrasta. Med. sovet. 2015; 6: 18–23. [in Russian]
21. Иванова Н.А., Костракина Л.Н. Опыт применения Бепантена и Бепантена плюс в лечении атопического дерматита у детей. Сonsilium Medicum. Педиатрия (Прил.). 2005; 1: 39–41. / Ivanova N.A., Kostrakina L.N. Opyt primeneniia Bepantena i Bepantena plius v lechenii atopicheskogo dermatita u detei. Sonsilium Medicum. Pediatrics (Suppl.). 2005; 1: 39–41. [in Russian]
22. Lynde C, Barber K, Claveau J et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg 2005; 8 (Suppl. 5): 1–9: 12.
________________________________________________
2. Vijayanand P, Seumois G, Simpson LJ et al. Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity 2012; 36 (2): 175–87.
3. Reshetilo O.V., Stoeva T.V., Vesilyk N.L. Vliianie atopicheskogo dermatita na kachestvo zhizni detei i roditelei. Mezhdunar. nauchno-issledovatel'skii zhurn. 2015; 9 (40): 65–7. [in Russian]
4. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 2006; 60 (8): 984–92.
5. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118 (1): 152–69.
6. Guidelines for treatment of atopic eczema (atopic dermatitis); part I.
7. Ring J, Alomar A, Bieber T et al. European Dermatology Forum (EDF), European Academy of Dermatology and Venereology (EADV), European Federation of Allergy (EFA), European Task Force on Atopic Dermatitis (ETFAD), European Society of Pediatric Dermatology (ESPD). Global Allergy and Asthma European Network (GA2LEN). J Eur Acad Dermatol Venereol 2012; 26 (8): 1045–60.
8. Rubel D, Thirumoorthy T, Soebaryo RW et al. Consensus guidelines for the management of atopic dermatitis: an Asia-Pacific perspective. Asia-Pacific Consensus Group for Atopic Dermatitis. J Dermatol 2013; 40 (Issue 3): 160–71. DOI: 10.1111/1346-8138.12065
9. Moncrieff G, Cork M, Lawton S et al. Use of emollients in dry-skin conditions: consensus statement. Clin Exp Dermatol 2013; 38: 231–8.
10. Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol 2012; 30: 286–96.
11. Giam YC, Hebert AA, Dizon MV et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy 2016; 6 (2): 120–8.
12. Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol 2013; 31: 91–8.
13. Vickery BP. Skin barrier function in atopic dermatitis. Curr Opin Ped 2007; 19: 89–93.
14. Vu AT, Baba T, Chen X et al. Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 2010; 126: 985–93.
15. Kozman A, Yao Y, Bina P et al. Encoding a superantigen by Staphylococcus aureus does not affect clinical characteristics of infected atopic dermatitis lesions. Br J Dermatol 2010; 163: 1308–11.
16. Hachem JP, Crumrine D, Fluhr J et al. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity cohesion. J Invest Dermatol 2003; 121: 345–53.
17. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol 2005; 99: 703–15.
18. Pogosyan M.A. Khlorgeksidin – antiseptik, ne privodiashchii k bakteriorezistenstnosti. Biulleten' med. Internet-konferentsii. 2015; 5 (10): 1234–5. [in Russian]
19. Putet G, Guy B et al. Effect of Bepanten Ointment on the prevention and treatment of diaper rash on premature and full-term babies. Realites Pediatriques 2001; 63: 33–8.
20. Zaytseva S.V., Zastrozhina A.K., Murtazaeva O.A. Osobennosti kozhnogo bar'era u rebenka rannego vozrasta. Med. sovet. 2015; 6: 18–23. [in Russian]
21. Ivanova N.A., Kostrakina L.N. Opyt primeneniia Bepantena i Bepantena plius v lechenii atopicheskogo dermatita u detei. Sonsilium Medicum. Pediatrics (Suppl.). 2005; 1: 39–41. [in Russian]
22. Lynde C, Barber K, Claveau J et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg 2005; 8 (Suppl. 5): 1–9: 12.
Авторы
Е.В.Дворянкова, Д.Р.Мильдзихова, И.М.Корсунская*
ФГБУН Центр теоретических проблем физико-химической фармакологии РАН. 119991, Россия, Москва, Ленинский пр-т, д. 38а, корп. 1
*marykor@bk.ru
Center for Theoretical Problems of Physicochemical Pharmacology. 119991, Russian Federation, Moscow, Leninskiy pr-t, d. 38a, korp. 1
*marykor@bk.ru
ФГБУН Центр теоретических проблем физико-химической фармакологии РАН. 119991, Россия, Москва, Ленинский пр-т, д. 38а, корп. 1
*marykor@bk.ru
________________________________________________
Center for Theoretical Problems of Physicochemical Pharmacology. 119991, Russian Federation, Moscow, Leninskiy pr-t, d. 38a, korp. 1
*marykor@bk.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.